Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.

Site-directed M2 proton channel inhibitors enable synergistic combination therapy for rimantadine-resistant pandemic influenza.

Pandemic influenza A virus (IAV) remains a significant threat to global health. Preparedness relies primarily upon a single class of neuraminidase (NA) targeted antivirals, against which resistance is steadily growing. The M2 proton channel is an alternative clinically proven antiviral target, yet a...

Full description

Bibliographic Details
Main Authors: Claire Scott, Jayakanth Kankanala, Toshana L Foster, Daniel H Goldhill, Peng Bao, Katie Simmons, Marieke Pingen, Matthew Bentham, Elizabeth Atkins, Eleni Loundras, Ruth Elderfield, Jolyon K Claridge, Joseph Thompson, Peter R Stilwell, Ranjitha Tathineni, Clive S McKimmie, Paul Targett-Adams, Jason R Schnell, Graham P Cook, Stephen Evans, Wendy S Barclay, Richard Foster, Stephen Griffin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-08-01
Series:PLoS Pathogens
Online Access:https://doi.org/10.1371/journal.ppat.1008716

Internet

https://doi.org/10.1371/journal.ppat.1008716

Similar Items